Key Takeaways
- Sun Pharmaceutical Industries has reached an agreement to acquire Organon & Co through an all-cash transaction that places the enterprise value at $11.75 billion with debt included.
- Shareholders of Organon will be compensated with $14.00 in cash for each share they hold.
- Shares of Organon skyrocketed approximately 31% on Friday following initial media reports, followed by an additional ~15% surge during Monday’s premarket session.
- Once merged, the new entity will be positioned among the world’s 25 largest pharmaceutical companies, boasting combined pro forma revenues reaching $12.4 billion.
- The transaction timeline anticipates completion in early 2027, contingent upon obtaining necessary regulatory clearances and shareholder consent.
India’s pharmaceutical giant Sun Pharma revealed on Sunday its intention to purchase the New Jersey-headquartered Organon & Co in a transaction fully backed by cash, totaling $11.75 billion when debt obligations are factored in. Shareholders will receive $14.00 for every share they own.
Shares of Organon had already experienced a dramatic climb of nearly 31% on Friday when the Economic Times initially disclosed that Sun Pharma was engaged in acquisition discussions for approximately $13 billion. Following Sunday’s formal announcement, Organon’s stock price accelerated upward by another ~15% during early Monday premarket activity.
Combining both trading sessions, the stock has registered an impressive gain of approximately 46% from its pre-announcement trading levels.
Organon emerged as an independent entity following its 2021 separation from Merck, concentrating its operations on women’s healthcare products, biosimilar medications, and established brand-name pharmaceuticals. The company disclosed revenues of $6.2 billion alongside adjusted EBITDA of $1.9 billion for the 2025 fiscal year.
Sun Pharma has outlined its financing strategy for the acquisition, which combines existing cash reserves with secured bank credit facilities. The transaction has received unanimous approval from both companies’ boards of directors.
Strategic Advantages for Sun Pharma
The acquisition provides Sun Pharma with immediate access to a diverse portfolio exceeding 70 pharmaceutical products distributed throughout more than 140 nations worldwide. Additionally, it establishes the Indian pharmaceutical company’s entry into the biosimilars market, where the newly formed organization would claim the seventh-largest market position globally.
Organon maintains significant commercial presence in strategic territories including the United States, European markets, China, Canada, and Brazil. The company’s manufacturing infrastructure encompasses six production facilities strategically located across the European Union and developing markets.
Dr. Kunal, an analyst at Macquarie, characterized the transaction as “strategically and financially compelling” for Sun Pharma. He emphasized that the consolidated company will derive 27% of its revenue stream from innovative pharmaceutical products, representing an increase from Sun Pharma’s current standalone figure of 20%.
Sun Pharma maintains its current focus on dermatological treatments, ophthalmology solutions, and onco-dermatology products within its innovative medicines division. The integration of Organon’s comprehensive women’s health product line would substantially broaden that therapeutic reach.
The post-merger organization would also secure a top-three competitive position in the worldwide women’s health pharmaceutical sector.
Financial Debt Considerations
Organon enters this transaction with existing debt obligations totaling $8.6 billion, offset by cash holdings of $574 million as reported in December 2025. The company’s net debt to EBITDA multiple stood at 4 times prior to the deal announcement.
In contrast, Sun Pharma maintained a net cash-positive financial position before this acquisition announcement. Following the transaction’s completion, analysts project the combined organization will operate with a net debt to EBITDA ratio of 2.3 times.
Equirus Capital’s Bhavesh Shah observed that acquisitions of this magnitude “can be value accretive over the medium to long term,” while cautioning about potential near-term headwinds such as integration expenditures and operational execution challenges.
This marks Sun Pharma’s sixth major acquisition over the past 16 years. The company’s acquisition history includes its 2007 purchase of struggling Israeli pharmaceutical firm Taro Pharma and the 2014 acquisition of Ranbaxy Laboratories in a deal valued at approximately $3.2 billion.
The Organon acquisition is projected to elevate Sun Pharma’s ranking into the top 25 global pharmaceutical companies, with the combined organization generating pro forma revenues of $12.4 billion.
The deal is scheduled to reach completion in early 2027, pending successful navigation of regulatory review processes and shareholder approval votes.
